Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

CN37 - Precision medicine is in clinical practice but is not an assimilated concept

Date

16 Sep 2021

Session

ePoster Display

Topics

Targeted Therapy;  Patient Education and Advocacy

Tumour Site

Presenters

Audrey GARIBBO-SARKISSIAN

Citation

Annals of Oncology (2021) 32 (suppl_5): S1270-S1272. 10.1016/annonc/annonc695

Authors

A. GARIBBO-SARKISSIAN1, C. Bourrières1, L. Youinou1, M. Micheloni2, S. Rico1, A. Riben1, N. Vieillard1

Author affiliations

  • 1 Bouches-du-rhône, Association Onco-Partage, 13009 - Marseille/FR
  • 2 Precision Medicine, ROCHE SAS, Boulogne-Billancourt/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract CN37

Background

Molecular tests are the basis of precision medicine and can provide specific treatment for cancer. These tests are regularly proposed, but are caregivers and patients sufficiently informed?

Methods

The association Onco-Partage involved in health literacy carried out a knowledge survey on the subject with a panel of caregivers and patients. Based on this observation, it has co-constructed, in partnership with Roche, a complex program of therapeutic patient education (TPE). Finally, it conducted a new survey to evaluate the interest of this approach.

Results

Between May and June 2020, 92 people completed a patient/caregiver mirror survey ( n = 23 and 69 respectively). Although only 50% of caregivers have received training on precision medicine, its purpose and positioning in the care pathway are clear. However, only 50% report having discussed it with their patients. They feel helpless to answer questions about the technique or significance of the test in an optimal way. As a result, patients have mostly non-professional information and the concept is unclear and anxiogenic. Confusion exists about the indication, technique and meaning of the test and genetic analyses. For more than 1/3 of them, the quality of the information could have reduced this anxiety. Between June and December 2020, the first axis of a TPE of 5 (what is a molecular test? for whom? why? when? how?) was completed. A short video is available for caregivers and patients (who can watch it alone or during a TPE session). Before viewing the video, knowledge and anxiety levels related to the subject are recorded. At the end of the viewing, a short series of questions is used to determine the level of knowledge and the degree of anxiety. Between February and March 2021, pre- and post-viewing responses serve as a second survey (28 caregivers and 57 patients). As a result : 1) caregivers reported being twice as equipped to answer patients' questions; 2) patients had a better understanding and saw a decrease in their anxiety levels; 3) other topics were facilitated by viewing during a TPE session.

Conclusions

Precision medicine is a part of oncology, but it is not an easy concept. TPE is needed in order to reduce patients' anxiety and increase the patient/caregiver relationship.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Association Onco-Partage.

Funding

Roche SAS.

Disclosure

A. Garibbo-Sarkissian: Other, Institutional, Sponsor/Funding: Roche. M. Micheloni: Financial Interests, Personal, Officer: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.